Prev Close | 49.50 |
Open | 50.15 |
Day Low/High | 49.68 / 50.16 |
52 Wk Low/High | 36.15 / 64.94 |
Volume | 7.42M |
Prev Close | 49.50 |
Open | 50.15 |
Day Low/High | 49.68 / 50.16 |
52 Wk Low/High | 36.15 / 64.94 |
Volume | 7.42M |
Exchange | NASDAQ |
P/E Ratio | 51.70 |
Div & Yield | N.A. (N.A) |
Ever think you would see the day when all cash was digital so the federal government could place a negative interest rate (tax) on savings? I can see this coming from a mile away.
Here's my view on this space and where the money is to be made.
COVID numbers stopped improving a while ago, even with ever-improving rates of vaccination. Just what is going on here?
A break in a key support level could precipitate further declines in the life sciences company's shares.
Dips in the shares of Redhill Biopharma and FibroGen Inc. provided the chance for the author to employ his covered call strategy.
Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.
Who knew high finance was so easy? And why the heck was I working so hard? Fundamental analysis is so 1980s.
Here are some articles that I'll be perusing while I choke down my lunch today:Â American Airlines Uncorks Wine Delivery Program To Clear Shelves, Promote Travel MyFreeCams hack: 2 million user records stolen from top adult streaming site and sold o...
Aggressive traders might want to look past any near-term price weakness and consider a small long position.
We have to take both the private sector and the states out of the equation, and adopt the process that wiped out Polio.
While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.
I did something on Tuesday that I never thought that I would do again. I bought some Intel.
I think BA returns to normal as we do, as the airlines do... but with the defense contracting business as a foundation to rely upon.
The Russell 2000 is now up 7% for December, twice the increase for the Nasdaq Composite.
Ending the pandemic swiftly appears unlikely, so here's how to look at key stocks and sectors right now -- especially as concerns of new lockdowns grow.
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
Vaccines are on the move (a big plus) even as members of Congress continue to dawdle on a fiscal support package (a big minus).
Plus, stay nimble as the road just ahead could become a bit more treacherous than many may think.
The RMPIA also tops other indexes for year, shooting ahead 29%.
Governments around the world have committed to buying hundreds of millions of doses of AZD1222.
The battle to gain control over Covid-19 is entering a crucial stage and calls for continued determination.
All in all stick with the tipping pointers, they are the drivers of this and the next leg higher.
Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.
I will come back to these names over and over again as we are now in the sweet spot for many.
A lot has happened over the past couple weeks, but little has changed. Let's dig in.
None of these questions have been answered which is why I see chaos ahead as we can't even imagine this process working.
Basically, I think we laid out enough reasons for financial markets to revolt, yet they did not.